Peginterferon-α-2a
1
Reactions 1374 - 22 Oct 2011 S Peginterferon-α-2a Autoimmune haemolytic anaemia and thyroiditis: case report A 55-year-old woman developed autoimmune haemolytic anaemia and thyroiditis during treatment with peginterferon-α-2a for chronic hepatitis C. The woman started receiving ribavirin and SC peginterferon-α-2a 180 µg/week in February 2010. After 8 weeks, she developed haemolytic anaemia. Due to haemoglobin reduction, 16 weeks after treatment, she started receiving erythropoietin; however, no improvement was noted. Gradual withdrawal of ribavirin was started, and anaemia failed to reverse. At week 28 she received levothyroxine sodium for overt hypothyroidism. She presented during week 35, with easy fatigability and syncope. Bone marrow examinations revealed hypercellular erythroid series. Her thyroglobulin antibody and thyroid peroxidase antibody levels were 60.8/40 IU/mL and 48.9/34 IU/mL, respectively. Peginterferon-α-2a- induced autoimmune haemolysis was diagnosed. Peginterferon-α-2a was discontinued, but haemolysis and hypothyroidism progression did not cease. Six weeks after steroid induction, the woman’s haemoglobin and TSH levels had normalised, and antithyroid antibodies became negative. Author comment: "[B]aseline thyroid autoantibodies were not measured in our patient, consequently we could not predict the thyroid dysfunction in our patient, in addition we could not judge whether our patient was susceptible for autoimmune thyroiditis or developed de novo thyroiditis after [interferon] therapy." Said A, et al. Pegylated interferon de novo-induce autoimmune haemolytic anaemia in chronic hepatitis C patient. BMJ Case Reports : 2011. Available from: URL: http://dx.doi.org/10.1136/bcr.06.2011.4400 - Egypt 803061649 1 Reactions 22 Oct 2011 No. 1374 0114-9954/10/1374-0001/$14.95 © 2010 Adis Data Information BV. All rights reserved
Transcript of Peginterferon-α-2a
Reactions 1374 - 22 Oct 2011
SPeginterferon-α-2a
Autoimmune haemolytic anaemia and thyroiditis:case report
A 55-year-old woman developed autoimmunehaemolytic anaemia and thyroiditis during treatment withpeginterferon-α-2a for chronic hepatitis C.
The woman started receiving ribavirin and SCpeginterferon-α-2a 180 µg/week in February 2010. After8 weeks, she developed haemolytic anaemia. Due tohaemoglobin reduction, 16 weeks after treatment, shestarted receiving erythropoietin; however, no improvementwas noted. Gradual withdrawal of ribavirin was started, andanaemia failed to reverse. At week 28 she receivedlevothyroxine sodium for overt hypothyroidism. Shepresented during week 35, with easy fatigability andsyncope. Bone marrow examinations revealedhypercellular erythroid series. Her thyroglobulin antibodyand thyroid peroxidase antibody levels were 60.8/40 IU/mLand 48.9/34 IU/mL, respectively. Peginterferon-α-2a-induced autoimmune haemolysis was diagnosed.
Peginterferon-α-2a was discontinued, but haemolysisand hypothyroidism progression did not cease. Six weeksafter steroid induction, the woman’s haemoglobin and TSHlevels had normalised, and antithyroid antibodies becamenegative.
Author comment: "[B]aseline thyroid autoantibodies werenot measured in our patient, consequently we could notpredict the thyroid dysfunction in our patient, in addition wecould not judge whether our patient was susceptible forautoimmune thyroiditis or developed de novo thyroiditis after[interferon] therapy."Said A, et al. Pegylated interferon de novo-induce autoimmune haemolyticanaemia in chronic hepatitis C patient. BMJ Case Reports : 2011. Available from:URL: http://dx.doi.org/10.1136/bcr.06.2011.4400 - Egypt 803061649
1
Reactions 22 Oct 2011 No. 13740114-9954/10/1374-0001/$14.95 © 2010 Adis Data Information BV. All rights reserved
![Ursinyova, N. , Bedford, R. B., & Gallagher, T. (2016). Copper- … · alkyl halides and (b) with key modifications including an external iodide sourcetoprovideboronicester 2a .[a]Enantiomericpurityof](https://static.fdocument.org/doc/165x107/607b466c804c7425625e49f3/ursinyova-n-bedford-r-b-gallagher-t-2016-copper-alkyl-halides.jpg)
